CellSource Co Ltd
TSE:4880
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 107
1 664
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
CellSource Co Ltd
CellSource Co Ltd
Accounts Receivables
CellSource Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CellSource Co Ltd
TSE:4880
|
Accounts Receivables
¥361.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
CMIC Holdings Co Ltd
TSE:2309
|
Accounts Receivables
¥16.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
C
|
Chiome Bioscience Inc
TSE:4583
|
Accounts Receivables
¥60.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
7%
|
|
|
Precision System Science Co Ltd
TSE:7707
|
Accounts Receivables
¥649.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Medinet Co Ltd
TSE:2370
|
Accounts Receivables
¥225.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
WDB coco Co Ltd
TSE:7079
|
Accounts Receivables
¥1.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
CellSource Co Ltd
Glance View
CellSource Co., Ltd. engages in regenerative medicine related business. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 90 full-time employees. The company went IPO on 2019-10-28. The firm operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
See Also
What is CellSource Co Ltd's Accounts Receivables?
Accounts Receivables
361.5m
JPY
Based on the financial report for Oct 31, 2023, CellSource Co Ltd's Accounts Receivables amounts to 361.5m JPY.
What is CellSource Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
21%
Over the last year, the Accounts Receivables growth was -44%. The average annual Accounts Receivables growth rates for CellSource Co Ltd have been 17% over the past three years , 21% over the past five years .
You don't have any saved screeners yet
